Home > Cardiology > HFA 2022 > Letter from the Editor

Letter from the Editor

Editor
Prof. Marc Bonaca, University of Colorado, USA
Conference
HFA 2022
Dear Colleagues,

Thank you for your interest in this edition of Medicom’s Conference Report covering the annual Heart Failure Congress of the Heart Failure Association of the European Society of Cardiology that took place in Madrid, Spain in May 2022. This year’s meeting was filled with late-breaking clinical trials, innovative science and therapeutic device applications for heart failure patients.

In the following pages, you can read about outcomes from the latest clinical trials, including data for Omecamtiv mecarbil, Vutrisiran, Dapagliflozin and Finerenone in patients with heart failure. Also included are results from early phase investigations of novel therapies and mechanisms including cardiac contractility modulation therapy and splanchnic nerve ablation. In addition, there is a dedicated section focused on SGLT2 inhibitors and the broad learnings to date in the care of patients with heart failure. You will also find sections dedicated to novel therapeutic and diagnostic targets and thought-provoking links between cardiac wasting and cancer. As always, our summaries are written independently and are peer-reviewed for balance. We hope you find this edition informative, engaging, and balanced and thank you again for your readership.

Sincerely,

Marc

 



 

Biography

Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training, he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi



Posted on